The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between microRNA-126 and maintenance therapy with bevacizumab after bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results of the phase III Nordic ACT trial NCT00598156 translational study.
Torben Hansen
Research Funding - Roche/Genentech
Rene dePont Christensen
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Rikke Fredslund Andersen
No relevant relationships to disclose
Karen-Lise Garm Spindler
No relevant relationships to disclose
Flemming Brandt Soerensen
No relevant relationships to disclose
Anders Johnsson
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech (I)
Other Remuneration - Roche/Genentech
Anders Kristian Moeller Jakobsen
Research Funding - Roche